posted on 2013-10-24, 00:00authored byYong Wang, Joshua E. Mendoza-Elias, Meirigeng Qi, Tricia A. Harvat, Sang Joon Ahn, Dongyoung Lee, Diana Gutierrez, Hyojin Jeon, Daniel Paushter, José Oberholzer
Islet transplantation is a promising therapy for type 1 diabetes mellitus; however, success rates in achieving both short- and longterm
insulin independence are not consistent, due in part to inconsistent islet quality and quantity caused by the complex nature
and multistep process of islet isolation and transplantation. Since the introduction of the Edmonton Protocol in 2000, more
attention has been placed on preserving mitochondrial function as increasing evidences suggest that impaired mitochondrial
integrity can adversely affect clinical outcomes. Some recent studies have demonstrated that it is possible to achieve islet
cytoprotection by maintaining mitochondrial function and subsequently to improve islet transplantation outcomes. However, the
benefits of mitoprotection in many cases are controversial and the underlying mechanisms are unclear. This article summarizes
the recent progress associated with mitochondrial cytoprotection in each step of the islet isolation and transplantation process,
as well as islet potency and viability assays based on the measurement of mitochondrial integrity. In addition, we briefly discuss
immunosuppression side effects on islet graft function and how transplant site selection affects islet engraftment and clinical
outcomes.